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PATTERNS IN METASTATIC COLORECTAL CANCER IN WESTERN 
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OBJECTIVES: Treatment outcomes improved in metastatic colorectal cancer (mCRC) 
due to the introduction of the monoclonal antibodies (mAb) in combination with 
chemotherapy. This study described current treatment patterns of chemotherapy and 
mAbs in clinical practice in 4 EU countries. METHODS: This cohort study used 
physician-surveyed data from the LifeLinkTM Oncology Analyzer Database for mCRC 
patients in four EU countries (France, Germany, Italy, and Spain). All patients aged 
≥21 years at mCRC diagnosis were included. Treatment patterns in 2009 were exam-
ined descriptively by lines of therapy. RESULTS: The study sample includes 
2734 mCRC patients (61% male, median age category 61–70 years) with 862, 656, 
567, and 649 from France, Germany, Italy, and Spain, respectively. In 1st-line, more 
patients received FOLFOX-containing regimens than FOLFIRI-containing regimens in 
Germany (42% vs. 30%) and Spain (25% vs. 16%), while in Italy and France, the 
reverse was true (Italy: 34% FOLFIRI vs. 29% FOLFOX: France: 26% vs. 19%). In 
2nd-line, more patients received FOLFIRI-containing regimens than FOLFOX-con-
taining regimens in Germany (36% vs. 18%), Italy (29% vs. 14%), and Spain (34% 
vs. 6%), while similar proportions of FOLFOX and FOLFIRI were used in France 
(18% vs. 15%). In 1st line, Bevacizumab (Bmab) was administered to 44% of patients 
in Italy, 42% in France, 37% in Germany, and 30% in Spain, while Cetuximab 
(Cmab) use ranged from 14% in Spain to 7% in Italy. In 2nd-line, Bmab was used in 
37% of the patients in Germany, 38% in France, 33% in Italy, and 30% in Spain, 
while Cmab was used in 30% of the patients in Spain, followed by 26% in Italy, 20% 
in Germany and 17% in France. CONCLUSIONS: FOLFOX- and FOLFIRI-based 
regimens are common standard of care chemotherapies, and monoclonal antibodies 
are routinely combined with these chemotherapies.
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INEQUALITIES IN GEOGRAPHICAL ACCESS TO ONCOLOGY SERVICES 
IN GREECE AND THEIR IMPACT ON PATIENTS AND CARERS
Souliotis K1, Athanasakis K2, Palaka E3, Kyriopoulos II2, Golna C4, Kyriopoulos J2
1University of Peloponnese, Corinth, Corinth, Greece; 2National School of Public Health, 
Athens, Greece; 3Foundation of Economic and Industrial Research, Athens, Attica, Greece; 
4Roche Hellas SA, Athens, Greece
OBJECTIVES: Previous studies (NSPH 2008, 2009) demonstrated that clustering of 
oncology resources exceeds the spatial concentration pattern of health-care services in 
Greece, thus resulting to substantial cross-regional ﬂ ows of cancer patients. The objec-
tive of this study was to assess the impact of geographic accessibility on patients when 
selecting care and during treatment for cancer. METHODS: Face-to-face interviews 
with 106 patients diagnosed with cancer from three specialized anticancer hospitals 
(two Athens and one Thesaloniki). Questionnaire was designed by a specialized Delphi 
panel of the NSPH to capture patient preferences. Median patient age was 54.5 years. 
Data were analyzed using SPSS v.15.0. RESULTS: Patients across the board choose 
their hospital on the basis of specialization (50%), physician reference (41.5%), and 
hospital reputation (35.8%). Sixty-three percent of patients face access barriers, most 
commonly cost of health-care services (44.3%), distance from place of residence 
(37%), and demand on time (33%). 76.4% of patients return to place of residence at 
treatment intervals and 43.4% immediately after treatment. To receive treatment, 
23.6% stay at homes of relatives, 14.2% at hotels, and 1% in hospital-owned hos-
pices. Fifty percent of patients undergo treatment cycles repeating every 15–30 days. 
Patients travel predominately by own car (48.1%). 4.7% travel by taxi reimbursed by 
their insurance fund and 1% by hospital ambulance. 84% of patients travel accom-
panied by one or more carers. At treatment intervals, only 8% of patients are sup-
ported by physicians at place of residence. CONCLUSIONS: Signiﬁ cant cross-regional 
ﬂ ows of cancer patients to access adequate treatment lead to substantial direct and 
indirect costs for patients and their carers in a strained ﬁ nancial environment. Patients 
also face signiﬁ cant gaps in integrated support during treatment intervals. a shift in 
the organization of cancer services is essential for the system to be responsive to 
expressed patient needs especially during treatment.
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HEALTH RESOURCE UTILIZATION OF SUBJECTS RECEIVING 
DENOSUMAB AND ZOLEDRONIC ACID IN A RANDOMIZED PHASE 3 
TRIAL OF ADVANCED BREAST CANCER PATIENTS WITH BONE 
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OBJECTIVES: Bone metastases occur in up to 75% of patients with advanced breast 
cancer. Skeletal complications of bone metastases include pathologic fracture, spinal 
cord compression, and surgery and radiation to bone. In a recently completed trial of 
breast cancer patients with bone metastases, denosumab, a fully human monoclonal 
anti-RANKL antibody, was superior to zoledronic acid (ZA) in delaying/preventing 
skeletal related events (SRE). METHODS: Eligible patients (N = 1026, denosumab; 
N = 1020, ZA) received monthly subcutaneous denosumab 120 mg or intravenous 
ZA 4 mg in a double-bind, double-dummy design. Health resource utilization (HRU) 
data, excluding protocol-speciﬁ ed visits, were collected from all randomized patients 
monthly through end of study (median duration 17 months, both groups). RESULTS: 
Comparing patients who experienced any on-study SRE (n = 315, denosumab; n = 
372, ZA) with patients without an on-study SRE, a greater proportion reported at 
least one radiation oncology unit visit (22.9% vs. 8.7%), clinic visit (75.5% vs. 
71.1%), and inpatient hospitalization (62.9% vs. 48.6%). The mean number of clinic 
visits and inpatient hospitalizations was also greater for patients who experienced an 
on-study SRE. A between-treatment group comparison of denosumab versus ZA 
demonstrated that for patients with one or more clinic visits who experienced any 
on-study SRE, the denosumab group had 10% fewer mean clinic visits compared with 
the ZA group (15.5 vs. 17.2 visits). Additionally, mean radiation oncology clinic visits 
were decreased by 32% in the denosumab compared with the ZA group (4.2 vs. 6.2 
visits) and mean inpatient hospitalizations were decreased by 12% (3.7 vs. 4.2 hospi-
talizations). CONCLUSIONS: Regardless of treatment group, patients who had an 
on-study SRE had greater HRU compared with patients not experiencing an on-study 
SRE. In this study, among those with any on-study SRE, patients treated with deno-
sumab had fewer clinic visits, radiation oncology unit visits, and inpatient hospitaliza-
tions compared to patients treated with zoledronic acid.
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MEDICAL RESOURCES UTILIZATION OF FIVE MOST PREVALENT 
CANCERS IN TAIWAN (LUNG CANCER, LIVER CANCER, COLORECTAL 
CANCER, GASTRIC CANCER, AND BREST CANCER): 2001~2007
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OBJECTIVES: We want to study the real cost structure of cancer treatment using the 
National Health Insurance Research Database (NHIRD) from Taiwan. METHODS: 
This study adopted a retrospective observational design and the data were retrieved 
from the NHIRD, which is managed by the National Health Research Institutes 
(NHRI). We used descriptive statistical methods to display data and time trend. 
RESULTS: The number of patients with these ﬁ ve cancers showed an increasing trend 
in these 7 years. Breast cancer had the highest annual increase (7.34%), followed by 
colorectal cancer (3.75%). Lung cancer and breast cancer had the highest average 
outpatient cost for each patient per year, while lung cancer, colorectal cancer, and 
gastric cancer had the highest average inpatient cost for each patient per year. The 
annual increase rates in the total cancer treatment cost for liver cancer, lung cancer, 
colorectal cancer, gastric cancer, and breast cancer were 10.70%, 11.61%, 16.73%, 
18.38%, and 17.21% respectively. We divided the cost structure of cancer treatments 
into chemotherapy, hormone therapy, and supportive treatment. The highest percent-
ages of chemotherapy and hormone therapy were for colorectal cancer (more than 
95%) and for breast cancer (more than 11%). On average, the annual increase rates 
in the cancer chemotherapy cost per patient for liver cancer, lung cancer, colorectal 
cancer, gastric cancer, and breast cancer were respectively 3.59%, 3.66%, 9.86%, 
16.78%, and 11.72%. CONCLUSIONS: This study showed a positive correlation 
between annual cancer patient number and NHI reimbursement, and an increasing 
trend for chemotherapy, hormone therapy, and supportive treatment. The results also 
showed that the number of the total amount of NHI reimbursement and the drug 
costs had increasing trends in these 7 years. This increased the ﬁ nancial burden of 
cancer patients and may alter the allocation of NHI resources.
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OBJECTIVES: New imaging tests such as computed tomography (CT), [18F]ﬂ uoro-
deoxyglucose-positron emission tomography (FDG-PET) scanning, and magnetic reso-
nance imaging (MRI) are not recommended for staging or follow-up of asymptomatic 
patients with EBC according to current guidelines. However, frequently these tests are 
requested even in the absence of a clinical indication. The purpose of this study was 
to evaluate how the availability of new imaging techniques has changed staging and 
follow-up modalities in EBC patients and to estimate its cost implications. METHODS: 
We analyzed clinical computerized information from 457 general practitioners assist-
ing an average of 630,000 inhabitants of the Campania region in the south of Italy. 
Incident EBC cases were selected and divided into calendar years from 2005 to 2008. 
The mean number of diagnostic tests prescribed per patient (N/Pt) and the mean costs 
per patient were evaluated during the ﬁ rst post-diagnosis year. The mean was com-
pared between each year using one-way analysis of variance. Costs were expressed in 
Euros (mean ± SD). RESULTS: We identiﬁ ed 576, 489, 474, and 497 newly diagnosed 
cases of EBC in 2005, 2006, 2007, and 2008, respectively. Overall, there was a sig-
niﬁ cant increase of the mean number of imaging tests prescribed per patient from 
2005 to 2008 (P < 0.0001). No change of the mean number of mammograms, bone 
scan, and chest x-ray requested per patient was observed. The mean costs per patient 
also signiﬁ cantly increased from c354.96 ± 581.32 in 2005 to c546.78 ± 837.36 in 
2008 (P = 0.004). CONCLUSIONS: CT, FDG-PET, and MRI employment for EBC 
patients in daily clinical practice has been steadily growing over the past 4 years with 
cost repercussions. However, there are no data to support their role in routine breast 
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cancer staging or surveillance in asymptomatic patients. Further studies are needed to 
characterize patients’ typology who deserve intensive staging and follow-up 
procedures.
PCN149
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OBJECTIVES: Radiotherapy with protons is a promising new treatment modality, for 
which adoption decisions are being made worldwide. However, the investment costs 
of proton therapy (PT) are high (roughly c90 million) and limited clinical evidence is 
available. Also, previous studies have indicated that PT may be cost-effective, but show 
considerable decision uncertainty. Consequently, it is unclear whether we should 
adopt PT now, or wait for more information. Adoption involves a risk of facing high 
sunk costs, while delay may impose opportunity losses because patients receive sub-
optimal treatment. Real options analysis (ROA), a technique originating from ﬁ nancial 
economics, assists in making this trade-off. METHODS: We examined whether to 
adopt PT, as compared to stereotactic body radiotherapy, in the treatment of stage I 
non-small cell lung cancer (NSCLC). Three options are available: adopt without 
further research (AN); adopt and undertake a trial (AT); or delay and undertake a 
trial (DT). The decision depends on the expected net gain of each option, which is 
calculated by subtracting its total costs from its expected beneﬁ ts. RESULTS: The 
expected net gain of at and DT were positive, indicating that we should not decide to 
adopt without further research (AN). Up to a sample size of 1000 patients, the 
expected net gain of at was higher than DT, indicating that the best option was to 
adopt and trial. The expected net gain of at was highest for a sample size of 450 
patients, which is thus considered the optimal sample size. CONCLUSIONS: Based 
on these results, we recommend to adopt PT in the treatment of stage I NSCLC, and 
to perform a trial with 450 patients. We have shown that ROA provides a transparent 
method of weighing the costs and beneﬁ ts of all available options, to assist in decision-
making upon new and expensive technologies.
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SYSTEMATIC LITERATURE REVIEW ON THE INTER AND INTRA 
LABORATORY VARIABILITY OF MOLECULAR TESTING OF RESPONSE 
TO TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS 
AND THE ASSOCIATED COSTS AND COST-EFFECTIVENESS
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OBJECTIVES: During disease monitoring of patients with CML, for patients with a 
complete response, residual leukemia can be assessed by real-time quantitative 
polymerase chain reaction (RQ-PCR). There are several “home-brew” and commer-
cially available BCR-ABL gene transcript detection methodologies in use, each 
requiring internal validation for the speciﬁ c laboratory and giving rise to laboratory-
speciﬁ c data. Harmonization of results according to an international scale is under-
way, but use is limited for several technical reasons. Information is required for 
decision makers on the accuracy and reproducibility of the tests and their costs 
and cost-effectiveness. The objective of this study was to assess the quantity and 
quality of such information. METHODS: English language systematic literature 
review on the intra- and inter-laboratory variability for BCR-ABL molecular monitor-
ing testing, inter-rater reliability across manual assays and the costs and cost-effec-
tiveness of molecular testing in CML. RESULTS: From 88 papers retrieved for detailed 
analysis, we found no studies which conducted a repeated test procedure on the same 
patient sample using the same technical approach in the same laboratory. There are 
a large number of studies which have compared alternative approaches using the same 
patient sample in molecular monitoring in the same laboratory. Several well-conducted 
studies have examined the variability of results from different laboratories in con-
trolled environments. We found no studies which compared inter-rater reliability or 
examined the costs or cost-effectiveness of molecular testing in CML. CONCLU-
SIONS: There is a reasonable body of evidence on certain aspects of analytical validity 
for CML molecular testing, but other aspects of analytical validity and the costs and 
economics of molecular diagnostics in CML appear to be an unresearched area. 
Testing variability has potentially serious implications for patient outcomes and more 
information for decision-makers to assess relative costs and cost-effectiveness is 
required.
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OBJECTIVES: The oncology market has become one of the major focus areas for 
pharmaceutical and biotech ﬁ rms. As of March 2009, 15,752 of 39,747 Phase I, II, 
and III trials listed on clinicaltrials.gov were related to cancer (approximately 40%). 
This large interest in oncology stems from market success of cancer therapies launched 
in the past decade and the existence of high unmet need to treat different types of 
cancers. As the number of FDA approved cancer therapies increases, there is a need 
to understand treatment patterns of these cancer drugs. METHODS: To understand 
the trends in usage and sales of cancer therapies, we analyzed the US market (sales 
and prescription) 2005–2008 data for all FDA-approved cancer drugs. Drugs were 
categorized as targeted cancer therapies, chemotherapies, monoclonal antibodies, 
small molecules, branded, and generics. RESULTS: During the past 5 years, the usage 
of both targeted cancer therapies and chemotherapy drugs has increased by high 
double digit rates. From 2005 to 2008, the total prescriptions for targeted cancer 
therapies and chemotherapies increased by 66% and 30%, respectively. While the 
sales of both types of these drugs are expanding, the majority of sales growth is 
attributed to an increasing uptake of targeted cancer drugs. The sales share of targeted 
cancer therapies in the US oncology market increased from 36% in 2004 to 56% in 
2008. Among targeted cancer therapies, majority (more than 75%) of uptake belongs 
to monoclonal antibodies. CONCLUSIONS: The usage and sales trends show a sig-
niﬁ cant increase in the use of cancer drugs. The high usage of targeted cancer therapies 
versus chemotherapies shows the rapidly changing nature of cancer treatment 
regimen.
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OBJECTIVES: This paper examines how different payers and health technology 
assessment (HTA) agencies recognize and reward innovation, using treatments for 
breast and colorectal cancer as case studies. METHODS: Breast and colorectal 
cancer were chosen given the extent of clinical advancements to date and supporting 
publicly available data. Sixteen cancer medicines across these two tumor types were 
considered. For each medicine/indication, the reimbursement decision and the reasons 
behind it were obtained from assessment reports published by the respective agencies 
in Australia, Canada, England and Wales, France, and Scotland. RESULTS: Seventy-
seven decisions were reviewed (39 and 38 for breast and colorectal cancer, respec-
tively). Twenty-four (62%) and 16 (42%) were positive for breast and colorectal 
cancer, respectively, while 21% and 45% were negative. In general, HTA agencies 
appear to consider advancements in breast cancer treatments as representing good 
uses of health-care resources with some assessments yielding less positive or more 
restrictive results. The majority of appraisals for newer colorectal cancer treatments 
have failed to receive positive recommendations. CONCLUSIONS: We identiﬁ ed some 
broad areas where differences of approach have led to different decisions. These relate 
to the: 1) acceptability of surrogate end points (e.g., progression-free survival) in cases 
where improvement in overall survival has not been established; 2) extent to which 
agencies formally consider input from clinical and patient representative organizations 
as part of their decision-making process; 3) methods used to assess medicines where 
pivotal trial did not use a comparator reﬂ ecting standard therapy; and 4) mechanisms 
for re-review or adopting performance-based risk-sharing arrangements following 
rejection due to uncertain clinical and/or cost-effectiveness. Addressing these issues 
may improve the likelihood of innovative medicines meeting reimbursement require-
ments, for breast and colorectal cancer as well as other therapeutic areas, thereby 
increasing the overall health beneﬁ t from pharmaceutical development that accrue to 
patients.
PCN154
A COMPARISON OF HTA RECOMMENDATIONS FOR CANCER 
TREATMENT TECHNOLOGIES PUBLISHED BY AGENCY FOR HEALTH 
TECHNOLOGY ASSESSMENT (AHTAPOL) AND NATIONAL INSTITUTE 
FOR HEALTH AND CLINICAL EXCELLENCE (NICE)
Kiljan A, Kolasa K, Hermanowski T
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OBJECTIVES: The objective of this study was to compare HTA recommendations 
for cancer drug technologies issued by both Agency for Health Technology 
Assessment (AHTAPol) in Poland and National Institute for Health and Clinical 
Excellence (NICE) in the UK. METHODS: The review of HTA recommendations 
concerning cancer technologies published online in the period August 2007–June 2010 
(AHTAPol) and March 2000–June 2010 (NICE) was performed. The classiﬁ cation of 
HTA recommendations based on Raftery’s approach labeling them as positive, posi-
tive with major or minor restriction, and negative was conducted. Negative guidance 
was categorized as clinical or nonclinical. Reasons for HTA recommendations for drug 
technologies appraised by both AHTAPoL and NICE were compared. Contradictory 
and noncontradictory recommendations were identiﬁ ed as well. RESULTS: A total of 
149 drug technologies were appraised by AHTAPol, of which 39 concerned cancer 
technologies (seven resubmissions). NICE published 136 drug appraisals, of which 59 
related to cancer technologies (12 resubmissions). In total, 12 cancer drug technologies 
were appraised by both AHTAPoL and NICE. Among them, there were nine contra-
dictory and three noncontradictory pairs of guidance (two negative and one positive). 
In the group of drug technologies appraised by both agencies, there were 42% and 
67% positive HTA recommendations issued by AHTAPoL and NICE, respectively. 
Negative recommendations based on nonclinical reasons prevailed in Poland (58%). 
At the same time, there were as many positive recommendations with major restric-
tions (33%) as negative recommendations based on nonclinical reason (33%) in the 
UK. The positive guidance without restriction constituted 8% and 17% of all apprais-
als for cancer drug technologies published by AHTAPol and NICE, respectively. 
